Avita Medical

227 articles with Avita Medical

• AVITA Medical Reports First Fiscal Quarter 2022 Financial Results

  11/8/2021

  AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, reported financial results for its first fiscal quarter ended September 30, 2021.

• Regional Burn Conferences Feature 12 RECELL® System Data Presentations by Prominent Burn SurgeonsData underscores broad clinical utility and health economic benefits of the RECELL® System

  10/28/2021

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), announced today that 12 RECELL® System data presentations will be shared at the upcoming Southern and Northeast Regional Burn Conferences.

• AVITA Medical to Announce Fiscal First Quarter 2022 Financial Results

  10/25/2021

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today it plans to release its fiscal first quarter 2022 financial results after the market closes on Monday, November 8, 2021.

• AVITA Medical to Present at the 2021 Cantor Virtual Global Healthcare Conference

  9/13/2021

  AVITA Medical, Inc. announced today that its management will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 4:00 p.m. Eastern Daylight Time

• AVITA Medical to Participate at the Lake Street 2021 BIG5 Conference

  8/31/2021

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that its management will participate at the Lake Street 2021 BIG5 Conference on Tuesday, September 14, 2021

• AVITA Medical Reports Fourth Quarter and Fiscal Year 2021 Financial Results

  8/26/2021

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (Company), today reported financial results for its fourth quarter of fiscal year 2021, ended June 30, 2021.

• FDA Approves IDE Amendment to a Single-Arm Design for AVITA Medical’s Pivotal Study of the RECELL® System for Vitiligo Treatment

  8/16/2021

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s request to amend its pivotal clinical trial evaluating the safety and effectiveness of the RECELL® System for the repigmentation of stable vitiligo lesions to a streamlined single-arm trial design.

• AVITA Medical to Announce Fiscal Fourth Quarter 2021 Financial Results

  8/12/2021

  AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced it plans to release its fiscal fourth quarter 2021 financial results after the market closes on Thursday, August 26, 2021.

• AVITA Medical Announces Inclusion in the Russell 3000 Index - June 29, 2021

  6/29/2021

  AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced that as part of the annual reconstitution of the Russell stock indexes, AVITA Medical has been added to the Russell 3000® Index effective June 28, 2021.

• AVITA Medical Announces Preliminary Fourth Quarter 2021 Financial Results

  6/15/2021

  AVITA Medical, Inc. today announced preliminary, unaudited financial results for the fiscal fourth quarter 2021.

• U.S. Food and Drug Administration Approves Expanded Use of the RECELL® System for the Treatment of Extensive Burns and Pediatric Patients

  6/10/2021

  AVITA Medical, Inc. announced that the U.S. Food and Drug Administration has approved expanded use of the RECELL® System in combination with meshed autografting for the treatment of all sizes of acute full-thickness thermal burn wounds for both pediatric and adult patients.

• AVITA Medical Reports Third Quarter 2021 Financial Results

  5/13/2021

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its third quarter of fiscal year 2021, ended March 31, 2021

• AVITA Medical to Announce Fiscal Third Quarter 2021 Financial Results

  4/29/2021

  AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced it plans to release its fiscal third quarter 2021 financial results after the market closes on Thursday, May 13, 2021.

• New RECELL® System Data to be Presented at 43rd Annual John A. Boswick Burn & Wound Care Symposium

  4/15/2021

  Presentations include data highlighting real-world use of RECELL in combination with complementary treatments, clinical versatility, and cost effectiveness of RECELL to advance patient care

• 15 RECELL® System Abstracts Accepted for Presentation at 53ʳᵈ Annual American Burn Association MeetingRecord Number of Accepted Abstracts Highlight Benefits of RECELL System and Reinforce Rapid Adoption by Surgeons to Advance Burn Care

  3/30/2021

  AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced that 15 abstracts highlighting the clinical and cost-savings benefits of the RECELL® Autologous Cell Harvesting Device have been accepted at the American Burn Association 53rd Annual Meeting.

• AVITA Medical, Inc. Names Michael Holder as Chief Financial Officer

  3/22/2021

  AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of Michael Holder as Chief Financial Officer effective March 22, 2021.

• Avita Medical, Inc. Announces Closing of Offering of 3,214,250 Shares of Common Stock

  3/1/2021

  AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced the successful closing of an underwritten registered public offering of its shares of common stock, the details of which were released to the market on February 24, 2021

• AVITA Medical, Inc. Announces Pricing of Its Public Offering of Common Stock - Feb 25, 2021

  2/25/2021

  AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced the pricing of its previously announced underwritten registered public offering of 2,795,000 shares of its common stock at a public offering price of US$21.50 per share.

• AVITA Medical to Present at Upcoming Investor Conferences

  2/18/2021

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that its management will present at the following upcoming investor conferences:

• AVITA Medical Reports Full Second Quarter 2021 Financial Results

  2/11/2021

  AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, reported financial results for its second quarter of fiscal year 2021, ended December 31, 2020.